NLRP3 and neoplasm: The genetic and pharmacological inhibition of NLRP3 inhibited the tumor infiltration of PMN-MDSCs and significantly enhanced the efficacy of Anti-PD-1 immunotherapy (Theivanthiran et al., 2020).